Vitrolife Beheer

Beheer criteriumcontroles 2/4

De CEO Vitrolife is Bronwyn Brophy O´Connor, benoemd in Aug2023, heeft een ambtstermijn van 1.25 jaar. De totale jaarlijkse vergoeding van { bedraagt SEK 7.44M, bestaande uit 74.5% salaris en 25.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.014% van de aandelen van het bedrijf, ter waarde € 372.50K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.3 jaar en 6.8 jaar.

Belangrijke informatie

Bronwyn Brophy O´Connor

Algemeen directeur

SEK 7.4m

Totale compensatie

Percentage CEO-salaris	74.5%
Dienstverband CEO	1.3yrs
Eigendom CEO	0.01%
Management gemiddelde ambtstermijn	1.3yrs
Gemiddelde ambtstermijn bestuur	6.8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Bronwyn Brophy O´Connor's beloning veranderd ten opzichte van Vitrolife's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-SEK 4b
Jun 30 2024	n/a	n/a	-SEK 4b
Mar 31 2024	n/a	n/a	-SEK 4b
Dec 31 2023	SEK 7m	SEK 6m	-SEK 4b

Compensatie versus markt: De totale vergoeding ($USD 673.62K ) Bronwyn } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 1.90M ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Bronwyn te vergelijken met de prestaties van het bedrijf.

CEO

Bronwyn Brophy O´Connor (50 yo)

1.3yrs

Tenure

SEK 7,439,000

Compensatie

Ms. Bronwyn Brophy O´Connor is President and Chief Executive Officer at Vitrolife AB (publ) since joining from August 01, 2023. She has an impressive track record as a leader of global Life science and Med...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Bronwyn Brophy O´Connor	CEO & President	1.3yrs	SEK 7.44m	0.014% € 372.5k
Patrik Tolf	Chief Financial Officer	2.8yrs	geen gegevens	0.0096% € 250.2k
Claus Bisgaard	Senior Vice President of Technologies	no data	geen gegevens	0.00028% € 7.3k
Guillermo Ferrando	Vice President Strategy & Corporate development	1.8yrs	geen gegevens	geen gegevens
Olivia Natens	Senior Vice President of Sales & Marketing	less than a year	geen gegevens	geen gegevens
Frank Pettersson	Acting Senior Vice President of HR & Sustainability	1.1yrs	geen gegevens	0.0013% € 34.1k
Rickard Ericsson	Senior Vice President of Consumables	less than a year	geen gegevens	0.0061% € 159.8k
Ricardo Capella	Senior Vice President Genetic Services	2.8yrs	geen gegevens	0.0044% € 115.5k

1.3yrs

Gemiddelde duur

53.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van VTFN wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.3 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Henrik Blomquist	Director	5.5yrs	SEK 883.00k	0.0081% € 211.7k
Jon Sigurdsson	Chairman of the Board	9.8yrs	SEK 16.30m	0.022% € 585.2k
Lars Holmqvist	Independent Director	6.8yrs	SEK 450.00k	geen gegevens
Pia Marions	Independent Director	11.6yrs	SEK 500.00k	0.0037% € 96.2k
Karen Soerensen	Independent Director	4.4yrs	SEK 500.00k	geen gegevens

6.8yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van VTFN wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.8 jaar).

Vitrolife Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Vitrolife AB (Publ) Announces Election Committee Appointments

Vitrolife AB (publ) Announces Election Committee Appointments

Vitrolife AB (publ) Announces Resignation of Maria Forss as Senior Vice President

Insufficient new directors

Vitrolife AB Announces Board Changes

Chief Financial Officer recently bought €47k worth of stock

Recent updates

Vitrolife AB (publ) to Report Fiscal Year 2024 Final Results on Mar 27, 2025

Vitrolife AB (publ) to Report Q4, 2025 Results on Jan 29, 2026

Third quarter 2024 earnings released: EPS: kr0.86 (vs kr0.90 in 3Q 2023)

Vitrolife AB (Publ) Announces Election Committee Appointments

Now 21% overvalued after recent price rise

Now 21% overvalued after recent price rise

Vitrolife AB (publ) to Report Q3, 2025 Results on Oct 29, 2025

Second quarter 2024 earnings released: EPS: kr1.06 (vs kr0.78 in 2Q 2023)

Now 19% undervalued after recent price drop

Now 19% undervalued after recent price drop

Now 20% undervalued after recent price drop

Vitrolife AB (publ) (OM:VITR) acquired Stb Zorg B.V.

Vitrolife AB (publ) (OM:VITR) signed an agreement to acquire Stb Zorg B.V. for €18 million.

Vitrolife AB (Publ) Approves Dividend for the Financial Year 2023

Upcoming dividend of kr1.00 per share

Now 24% undervalued

First quarter 2024 earnings released: EPS: kr0.85 (vs kr0.74 in 1Q 2023)

Dividend of kr1.00 announced

Full year 2023 earnings released: kr28.44 loss per share (vs kr2.91 profit in FY 2022)

Vitrolife AB (publ) to Report Fiscal Year 2023 Final Results on Mar 27, 2024

Vitrolife AB (Publ) Reports Non-Cash Impairment for the Fourth Quarter of 2023

Now 20% undervalued

Third quarter 2023 earnings released: EPS: kr0.90 (vs kr0.80 in 3Q 2022)

Vitrolife AB (publ) Announces Election Committee Appointments

Vitrolife AB (publ) Announces Resignation of Maria Forss as Senior Vice President

Insufficient new directors

Vitrolife AB Announces Board Changes

Investor sentiment deteriorates as stock falls 18%

New minor risk - Share price stability

Second quarter 2023 earnings released: EPS: kr0.78 (vs kr0.96 in 2Q 2022)

Vitrolife AB (publ) to Report Q3, 2024 Results on Oct 24, 2024

Investor sentiment improves as stock rises 15%

Chief Financial Officer recently bought €47k worth of stock

Upcoming dividend of kr0.85 per share at 0.4% yield

Full year 2022 earnings released: EPS: kr2.91 (vs kr2.98 in FY 2021)

Full year 2022 earnings released: EPS: kr2.91 (vs kr2.98 in FY 2021)

Vitrolife AB (publ) Proposes Dividend for 2022

Vitrolife AB (publ) Announces Executive Changes

Third quarter 2022 earnings released: EPS: kr0.80 (vs kr0.89 in 3Q 2021)

Vitrolife AB (publ) to Report First Half, 2023 Results on Jul 14, 2023

Vitrolife AB (publ) Announces Election Committee Appointments

Investor sentiment deteriorated over the past week

Now 20% undervalued after recent price drop

Vitrolife AB (Publ) Announces Retirement of Thomas Axelsson as CEO

Second quarter 2022 earnings released: EPS: kr0.96 (vs kr0.79 in 2Q 2021)

Vitrolife AB (publ), Annual General Meeting, Apr 27, 2023

Chief Financial Officer recently bought €48k worth of stock

First quarter 2022 earnings released: EPS: kr0.61 (vs kr1.09 in 1Q 2021)

First quarter 2022 earnings released: EPS: kr0.61 (vs kr1.09 in 1Q 2021)

Upcoming dividend of kr0.80 per share

Vitrolife AB (Publ) Proposes Dividend

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Vitrolife AB (Publ) Proposes Dividend

Third quarter 2021 earnings released: EPS kr0.89 (vs kr0.81 in 3Q 2020)

Second quarter 2021 earnings released: EPS kr0.79 (vs kr0.11 in 2Q 2020)

Vitrolife AB (publ) Approves Dividend for the Financial Year 2020

First quarter 2021 earnings released: EPS kr1.09 (vs kr0.73 in 1Q 2020)

Upcoming dividend of kr0.80 per share

Full year 2020 earnings released: EPS kr2.64 (vs kr3.53 in FY 2019)

Full year 2020 earnings released: EPS kr2.64 (vs kr3.53 in FY 2019)

Revenue misses expectations

New 90-day high: €22.60

Vitrolife AB (publ) to Report Fiscal Year 2020 Results on Feb 10, 2021

New 90-day low: €20.14

Third quarter 2020 earnings released: EPS kr0.81

Revenue beats expectations

Vitrolife AB (publ) to Report Fiscal Year 2020 Results on Mar 30, 2021

Vitrolife AB (publ) to Report Q1, 2021 Results on Apr 22, 2021

New 90-day low: €20.16